Anebulo Pharmaceuticals Inc

NASDAQ ANEB

Data sourced from iex and EODHD
Download Data

Anebulo Pharmaceuticals Inc Free Cash Flow for the year ending December 31, 2023: USD -9.68 M

Anebulo Pharmaceuticals Inc Free Cash Flow is USD -9.68 M for the year ending December 31, 2023, a -78.09% change year over year. Free Cash Flow is the cash flow available to a company after deducting capital expenditures from operating cash flow, indicating its ability to generate cash for expansion, debt repayment, or dividends.
  • Anebulo Pharmaceuticals Inc Free Cash Flow for the year ending December 31, 2022 was USD -5.44 M, a -11.62% change year over year.
  • Anebulo Pharmaceuticals Inc Free Cash Flow for the year ending December 31, 2021 was USD -4.87 M, a 0.00% change year over year.
  • Anebulo Pharmaceuticals Inc Free Cash Flow for the year ending December 31, 2020 was USD -4.87 M.
NASDAQ: ANEB

Anebulo Pharmaceuticals Inc

CEO Dr. Joseph F. Lawler M.D., Ph.D.
IPO Date May 7, 2021
Location United States
Headquarters 1415 Ranch Road 620 South, Lakeway, TX, United States, 78734
Employees 2
Sector Healthcare
Industry Biotechnology
Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

StockViz Staff

September 16, 2024

Any question? Send us an email